Dual Kinase inhibitor for Autoimmune disease

There are lots of JAK/TYK inhibitor project in drug discovery area. https://www.ncbi.nlm.nih.gov/pubmed/30113844 Here is an article from pfizer. Pfizer discovered and launched JAK inhibitor ‘tofacitinib’. Tofacitinib inhibits JAK3, JAK1 and JAK3. It is well known that JAK2 uniquely forms a homodimer, which is important in hematopoiesis via signal transduction associated with erythropoietin (EPO), thrombopoietin (TPO),Continue reading “Dual Kinase inhibitor for Autoimmune disease”